ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Funding Opportunities
Food and Drug AdministrationHHS-FDA

Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)

Funder: United States Food and Drug Administration

Posted Jul 11, 2025·Last checked Nov 18, 2026·open

AGENCY

Food and Drug Administration

PROGRAM

Discretionary

AMOUNT

$0 – $600K

CLOSES

Feb 8, 2028

Description

The purpose of this notice of funding opportunity (NOFO) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development. 

Eligibility

Others (see text field entitled "Additional Information on Eligibility" for clarification)

Contact

Stephanie Bogan Grantor

Kimberly.Pendleton@fda.hhs.gov

3018276802

Additional details

Department
HHS-FDA
Funding instrument
Grant
Cost sharing required
No
Archived
Mar 9, 2028

Opportunity number: RFA-FD-25-017

Quote this number when you contact the agency or apply.